News & Press Releases
News
QEDDI and o2h Discovery Celebrates 10 Years of Collaboration in Drug Discovery
3 Nov 2026
Press Release
o2h Discovery Welcomes Pioneer Group as a Platinum Partner to Support Biotech Innovatio
27 Oct 2026
Press Release
o2h Discovery Welcomes Persephoni Bio as a Platinum Partner to Support the Biotech Innovation
19 Oct 2026
Posters
Poster
Phenotypic & Targeted: Novel approaches to drug discovery
o2h Discovery has enhanced its biology expertise across therapeutic areas in Cambridge, UK, and Ahmedabad, India, utilizing advanced platforms to support
all stages of preclinical drug discovery, from target validation, hit identification through to lead optimisation and IND enabling. Our Integrated Drug Discovery
(IDD) approach combines biology, chemistry, and ADME capabilities to accelerate the design-make-test-analyze cycles. Our experienced biologists develop
customizable assays to support potency-to-efficacy translation and mechanism-of-action characterization, with seamless collaboration between our UK and
India teams. Specializing in small molecule drug discovery, we bring in-depth expertise in target biology, providing valuable insights that drive progress in
complex biology projects across a broad range of therapeutic areas.
28 Oct 2026
Poster
ChameLogK: A Rapid, High-Throughput Assay to Assess Bioavailability of Beyond Rule of Five Compounds
ChameLogK is a cutting-edge method for measuring chameleonicity, a vital factor in assessing cell permeability propensity of small molecules, including
‘Beyond Rule-of-Five’ such as PROTACs, macrocycles and peptides. Chameleonicity is ability of molecules to conformationally adapt to their environment,
driven by intramolecular hydrogen bonds; ChameLogK combines lipophilicity (BRlogD) and polarity (Δlog kw
IAM) descriptors. Leveraging literature methods,
o2h has developed a reliable, high-throughput platform to rapidly and inexpensively measure chameleonicity, accelerating optimization of Beyond Rule-ofFive therapeutic compounds
6 Sep 2025
Poster
An array of Targeted Degradation approaches offered as a part of integrated drug discovery services
Explore how o2h Discovery applies a PROTAC-like approach to RNA-targeted drug discovery. Our expertise in small molecule design, assay development, and RIBOTACs enables the creation of novel RNA degraders for next-generation therapeutics.
4 Feb 2025
Webinars
Webinar
Britain’s Most Exciting Human Health Companies
15 May 2020
Britain’s Most Exciting Human Health Companies
15 May 2020 |
15:00 BST
Our fourth o2h ChaiTime webinar was on Britain's most exciting human health companies and our special guest for this webinar was Andy Richards to chair a Q&A discussion with four o2h-backed exciting human health companies all of which are considering a Seed Plus or Series A funding round in the near future.
The panel featured an AI driven drug discovery company, a stem cell liver on-a-chip platform, a biotech focused on known recreational drugs for treatment of depression, and a company developing faster acting Insulin.
Webinar Chair:
Andy Richards, is an entrepreneur and investor and needs very little introduction in the UK Biotech community. He is and has been involved in many of the success stories that have come out of Cambridge, UK by either directly investing or supporting from the side lines and has spent a huge amount of his personal time supporting the sector over the last 25 years.
Panellists:
Ruchi Sharma, CEO and Founder of Stemnovate (www.stemnovate.co.uk)
Ruchi is 2020’s ‘one to watch’ top 21 entrepreneur and founded Stemnovate on the back of a $1m award from Innovate UK Innovate.
Peter Rands, CEO and Co-Founder of Small Pharma (www.smallpharma.co.uk)
Peter is both a passionate chemist and a trained patent attorney. They have a stealth programme that is progressing toward the clinic which uses a known active recreational drug to treat mental health conditions.
Sarah Howell, CEO of Arecor (www.arecor.com)
Sarah has made significant strides in building Arecor into a global leader focused on advancing today’s therapies to enable healthier lives. Arecor is a clinical-stage company, building a proprietary pipeline of next-generation therapeutic products and collaborating with many of the world’s largest pharma.
Szabolcs Nagy, CEO and Co-Founder of Turbine (www.turbine.ai)
Szabi has placed Turbine firmly on the map as one of the global leaders in the intersection of AI and pharmaceutical new drug discovery.
#o2hventures #ChaiTimeWebinar #DrugDiscovery
Webinar
Small Biotech and Big Pharma
22 May 2020
Small Biotech and Big Pharma
22 May 2020 |
15:00 BST
Our fifth executive o2h ChaiTime webinar was on ‘Small Biotech and Big Pharma’.
We live in an era where large pharma are hungry for breakthrough innovations and seek to collaborate with small biotech, and small biotech requires additional sources of capital and expertise. Janssen Pharmaceuticals, Inc, one of the Janssen Pharmaceutical Companies of Johnson & Johnson signed a collaboration in December 2019 with Nottingham University Spinout Exonate Ltd, headquartered in Cambridge.
o2h ChaiTime privileged to host the world's first fireside chat with CEO of Exonate, Catherine Beech and Pete Adamson, Vice President, DAS Head, Ophthalmology, Johnson & Johnson Medical Limited.
Webinar Host:
Sunil Shah, CEO @ o2h Group & o2h ventures
Panelists and Speakers:
Catherine Beech OBE, CEO of Exonate: Catherine trained as a Medical Doctor before embarking on a career in a big pharma. She then became a venture capital investor, followed by spearheading a string of new ventures. A real wonder woman!
Pete Adamson is the Vice President, DAS Head, Ophthalmology, Johnson & Johnson Medical Limited. Prior positions include President and Head of Discovery Ophthalmology at GlaxoSmithKline. He is one of the world's authorities on Ophthalmology Pharmaceutical Development.
#o2hventures #ChaiTimeWebinar #biotech
Webinar
Antibiotic Resistance – The Fight for Humanity
29 May 2020
Antibiotic Resistance – The Fight for Humanity
29 May 2020 |
15:00 BST
Our exclusive sixth o2h ChaiTime webinar was on "Antibiotic Resistance - The Fight for Humanity". According to the WHO, Antibiotic resistance is one of the biggest threats to global health, food security, and development today. Also, a growing number of infections – such as pneumonia, tuberculosis, gonorrhoea, and salmonellosis – are becoming harder to treat as the antibiotics used to treat them become less effective.
Let’s hope we can learn lessons from the Covid-19 pandemic - infectious organisms evolve constantly, so vigilance and pre-emptive action is required to maintain the tools we need to fight back.
We were honored to had Aleks Engel, Partner at Novo Holdings (Novo Seeds) chaired the sixth ChaiTime session.
Aleks quizzed some of the most innovative biotech companies in the space from both Cambridge and Oxford, in addition, we welcomed the Global Head, Infectious Diseases from global big pharma @Roche who are one of the pioneers/leaders in this battle.
Webinar Host:
Sunil Shah, CEO, o2h ventures, The Human Health EIS Fund
Webinar Chair:
Aleks Engel, Partner at Novo Holdings (Novo Seeds)
Panelists and Speakers:
Ken Bradley, Global Head, Infectious Disease Discovery at Roche Pharmaceutical Research and Early Development (pRED)
Ankit Mahadevia, CEO of NASDAQ listed, Spero Therapeutics
Paul Finn, CEO of Oxford University Spinout, Oxford Drug Design
Ajay Mistry, CEO of AI and antibiotics discovery start-up, Oppilotech
#o2hChaiTimeWebinar #antibioticresistance #drugdiscovery
